Abstract 309P
Background
Cholangiocarcinoma is a rare but highly lethal cancer type. It is divided into three anatomic subgroups: Intrahepatic (iCCA), perihilar (phCCA) and distal (dCCA) cholangiocarcinoma. This classification is crucial in therapeutic management. The aim of our retrospective study was to provide further information regarding epidemiology, anatomic subtypes and treatment strategies in patients treated in Lower Austria and to compare those with available literature.
Methods
A total of 301 patients treated across 10 institutions located in Lower Austria and who were diagnosed with CCA between 2008 and 2023, were included. Their data were extracted from a prospective recorded database.
Results
Of the analyzed patients 127 were female and 174 were male. The median age at diagnosis was 68 years. At the time of diagnosis, 126 patients (42%) were at an early potentially curative treatable stage and 175 (58%) at an advanced stage. The majority of analyzed patients (115) had iCCA, followed by pCCA (66) and dCCA (62). Data on anatomic subtype were unavailable for 58 patients The median time from diagnosis to initiation of treatment was 25 days for curative surgical intervention and 73 days for adjuvant treatment with capecitabine. The most common first-line therapy was a combination regimen with Cisplatin und Gemcitabine (76 patients/ 43%), followed by GEMOX (25 patients, 14%). Seven patients were treated with the current first-line standard regimen containing cisplatin/gemcitabine/durvalumab. The med. duration of first-line therapy was 125 days. Only a small number of 9 patients were treated with targeted therapy aiming at rare mutations in following genes: BRAF V600E (1), HER2 (3) and FGFR2 (2). Furthermore, 3 patients had undergone a treatment with the checkpoint inhibitor Pembrolizumab.
Conclusions
A significant proportion of the analyzed patients had iCCA, which contrasts with data available in the literature. Only a small fraction of patients obtained targeted therapy. All in all, further larger prospective studies should be conducted to verify our findings and to better assess tumor-specific characteristics, especially prognostic factors, which may prove valuable in providing adequate treatment options.
Legal entity responsible for the study
LGA.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.